Advertisement

Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Published:January 13, 2016DOI:https://doi.org/10.1016/j.amjcard.2015.12.058
      Genes associated with hypertrophic cardiomyopathy (HC) are not uniformly expressed in the atrial myocardium. Whether this may impact susceptibility to atrial fibrillation (AF) is unresolved. To analyze the prevalence and clinical correlates of AF in relation to genotype in a large HC cohort, prevalence and clinical profile of AF were assessed in 237 patients with HC, followed for 14 ± 10 years. Patients were divided into 3 genetic subgroups: (1) MYBPC3 (58%), (2) MYH7 (28%), and (3) “other genotypes” (14%; comprising TNNT2, TNNI3, TPM1, MYL2, complex genotypes, Z-line, and E-C coupling genes). Left atrial size was similar in the 3 subsets. AF occurred in 74 patients with HC (31%), with no difference among groups (31% in MYBPC3, 37% in MYH7 and 18% in other genotypes, p = 0.15), paroxysmal/persistent AF (12%, 18%, and 12%, respectively; p = 0.53), paroxysmal/persistent evolved to permanent (12%, 12%, and 3%, p = 0.36) or permanent AF (7%, 7%, and 3%, p = 0.82). Age at AF onset was younger in the group with other genotypes (37 ± 10 years) compared to the first 2 groups (53 ± 14 and 51 ± 17, respectively; p = 0.05) because of early onset associated with complex genotypes and a specific JPH2 mutation associated with abnormal intracellular calcium handling. At multivariate analysis, independent predictors of AF were atrial diameter (p ≤0.05) and age at diagnosis (p = 0.09), but not genetic subtype (p = 0.35). In conclusion, in patients with HC, genetic testing cannot be used in clinical decision making with regard to management strategies for AF. Genotype is not predictive of onset or severity of AF, which appears rather driven by hemodynamic determinants of atrial dilatation. Exceptions are represented by rare genes suggesting specific molecular pathways for AF in genetic cardiomyopathies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Olivotto I.
        • Cecchi F.
        • Poggesi C.
        • Yacoub M.H.
        Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.
        Circ Heart Fail. 2012; 5: 535-546
        • Maron B.J.
        • Maron M.S.
        Hypertrophic cardiomyopathy.
        Lancet. 2013; 381: 242-255
        • Maron B.J.
        • Ommen S.R.
        • Semsarian C.
        • Spirito P.
        • Olivotto I.
        • Maron M.S.
        Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
        J Am Coll Cardiol. 2014; 64: 83-99
        • Olivotto I.
        • Cecchi F.
        • Casey S.A.
        • Dolara A.
        • Traverse J.H.
        • Maron B.J.
        Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.
        Circulation. 2001; 104: 2517-2524
        • Olivotto I.
        • Maron B.J.
        • Cecchi F.
        Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy.
        Curr Cardiol Rep. 2001; 3: 141-146
        • Maron B.J.
        • Haas T.S.
        • Maron M.S.
        • Lesser J.R.
        • Browning J.A.
        • Chan R.H.
        • Olivotto I.
        • Garberich R.F.
        • Schwartz R.S.
        Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance.
        Am J Cardiol. 2014; 113: 1394-1400
        • Maron B.J.
        • Olivotto I.
        • Bellone P.
        • Conte M.R.
        • Cecchi F.
        • Flygenring B.P.
        • Casey S.A.
        • Gohman T.E.
        • Bongioanni S.
        • Spirito P.
        Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2002; 39: 301-307
        • Tian T.
        • Wang Y.
        • Sun K.
        • Wang J.
        • Zou Y.
        • Zhang W.
        • Bao J.
        • Zhu L.
        • Shen H.
        • Hui R.
        • Zhou X.
        • Song L.
        Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy.
        Cardiology. 2013; 126: 258-264
        • Gruver E.J.
        • Fatkin D.
        • Dodds G.A.
        • Kisslo J.
        • Maron B.J.
        • Seidman J.G.
        • Seidman C.E.
        Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation.
        Am J Cardiol. 1999; 83: 13H-18H
        • Eiras S.
        • Narolska N.A.
        • van Loon R.B.
        • Boontje N.M.
        • Zaremba R.
        • Jimenez C.R.
        • Visser F.C.
        • Stooker W.
        • van der Velden J.
        • Stienen G.J.
        Alterations in contractile protein composition and function in human atrial dilatation and atrial fibrillation.
        J Mol Cell Cardiol. 2006; 41: 467-477
        • Bassiouny M.
        • Lindsay B.D.
        • Lever H.
        • Saliba W.
        • Klein A.
        • Banna M.
        • Abraham J.
        • Shao M.
        • Rickard J.
        • Kanj M.
        • Tchou P.
        • Dresing T.
        • Baranowski B.
        • Bhargava M.
        • Callahan T.
        • Tarakji K.
        • Cantillon D.
        • Hussein A.
        • Marc Gillinov A.
        • Smedira N.G.
        • Wazni O.
        Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.
        Heart Rhythm. 2015; 12: 1438-1447
        • Olivotto I.
        • Girolami F.
        • Ackerman M.J.
        • Nistri S.
        • Bos J.M.
        • Zachara E.
        • Ommen S.R.
        • Theis J.L.
        • Vaubel R.A.
        • Re F.
        • Armentano C.
        • Poggesi C.
        • Torricelli F.
        • Cecchi F.
        Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy.
        Mayo Clin Proc. 2008; 83: 630-638
        • Biagini E.
        • Olivotto I.
        • Iascone M.
        • Parodi M.I.
        • Girolami F.
        • Frisso G.
        • Autore C.
        • Limongelli G.
        • Cecconi M.
        • Maron B.J.
        • Maron M.S.
        • Rosmini S.
        • Formisano F.
        • Musumeci B.
        • Cecchi F.
        • Iacovoni A.
        • Haas T.S.
        • Bacchi Reggiani M.L.
        • Ferrazzi P.
        • Salvatore F.
        • Spirito P.
        • Rapezzi C.
        Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy.
        Am J Cardiol. 2014; 114: 769-776
        • Belus A.
        • Piroddi N.
        • Ferrantini C.
        • Tesi C.
        • Cazorla O.
        • Toniolo L.
        • Drost M.
        • Mearini G.
        • Carrier L.
        • Rossi A.
        • Mugelli A.
        • Cerbai E.
        • van der Velden J.
        • Poggesi C.
        Effects of chronic atrial fibrillation on active and passive force generation in human atrial myofibrils.
        Circ Res. 2010; 107: 144-152
        • Piroddi N.
        • Belus A.
        • Scellini B.
        • Tesi C.
        • Giunti G.
        • Cerbai E.
        • Mugelli A.
        • Poggesi C.
        Tension generation and relaxation in single myofibrils from human atrial and ventricular myocardium.
        Pflugers Arch. 2007; 454: 63-73
        • Wann L.S.
        • Curtis A.B.
        • Ellenbogen K.A.
        • Estes N.A.
        • Ezekowitz M.D.
        • Jackman W.M.
        • January C.T.
        • Lowe J.E.
        • Page R.L.
        • Slotwiner D.J.
        • Stevenson W.G.
        • Tracy C.M.
        • Fuster V.
        • Ryden L.E.
        • Cannom D.S.
        • Crijns H.J.
        • Halperin J.L.
        • Le Heuzey J.
        • Kay G.N.
        • Olsson S.B.
        • Prystowsky E.N.
        • Tamargo J.L.
        Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 127: 1916-1926
        • Alfares A.A.
        • Kelly M.A.
        • McDermott G.
        • Funke B.H.
        • Lebo M.S.
        • Baxter S.B.
        • Shen J.
        • McLaughlin H.M.
        • Clark E.H.
        • Babb L.J.
        • Cox S.W.
        • DePalma S.R.
        • Ho C.Y.
        • Seidman J.G.
        • Seidman C.E.
        • Rehm H.L.
        Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity.
        Genet Med. 2015; 17: 880-888
        • Maron B.J.
        • Maron M.S.
        • Semsarian C.
        Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.
        J Am Coll Cardiol. 2012; 60: 705-715
        • Ho C.Y.
        • Charron P.
        • Richard P.
        • Girolami F.
        • Van Spaendonck-Zwarts K.Y.
        • Pinto Y.
        Genetic advances in sarcomeric cardiomyopathies: state of the art.
        Cardiovasc Res. 2015; 105: 397-408
        • Di Donna P.
        • Olivotto I.
        • Delcre S.D.
        • Caponi D.
        • Scaglione M.
        • Nault I.
        • Montefusco A.
        • Girolami F.
        • Cecchi F.
        • Haissaguerre M.
        • Gaita F.
        Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.
        Europace. 2010; 12: 347-355
        • Contreras-Valdes F.M.
        • Buxton A.E.
        • Josephson M.E.
        • Anter E.
        Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: long-term outcomes and clinical predictors.
        J Am Coll Cardiol. 2015; 65: 1485-1487
        • Reiser P.J.
        • Moravec C.S.
        Sex differences in myosin heavy chain isoforms of human failing and nonfailing atria.
        Am J Physiol Heart Circ Physiol. 2014; 307: H265-H272
        • Coppini R.
        • Ho C.Y.
        • Ashley E.
        • Day S.
        • Ferrantini C.
        • Girolami F.
        • Tomberli B.
        • Bardi S.
        • Torricelli F.
        • Cecchi F.
        • Mugelli A.
        • Poggesi C.
        • Tardiff J.
        • Olivotto I.
        Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.
        J Am Coll Cardiol. 2014; 64: 2589-2600
        • Beavers D.L.
        • Wang W.
        • Ather S.
        • Voigt N.
        • Garbino A.
        • Dixit S.S.
        • Landstrom A.P.
        • Li N.
        • Wang Q.
        • Olivotto I.
        • Dobrev D.
        • Ackerman M.J.
        • Wehrens X.H.
        Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization.
        J Am Coll Cardiol. 2013; 62: 2010-2019
        • Wang W.
        • Landstrom A.P.
        • Wang Q.
        • Munro M.L.
        • Beavers D.
        • Ackerman M.J.
        • Soeller C.
        • Wehrens X.H.
        Reduced junctional Na+/Ca2+-exchanger activity contributes to sarcoplasmic reticulum Ca2+ leak in junctophilin-2-deficient mice.
        Am J Physiol Heart Circ Physiol. 2014; 307: H1317-H1326
        • Hill J.A.
        • Diwan A.
        Ca(2+) leak in atrial fibrillation: junctophilin-2 stabilizes ryanodine receptor.
        J Am Coll Cardiol. 2013; 62: 2020-2022
        • Hong K.
        • Xiong Q.
        Genetic basis of atrial fibrillation.
        Curr Opin Cardiol. 2014; 29: 220-226
        • Coppini R.
        • Ferrantini C.
        • Yao L.
        • Fan P.
        • Del Lungo M.
        • Stillitano F.
        • Sartiani L.
        • Tosi B.
        • Suffredini S.
        • Tesi C.
        • Yacoub M.
        • Olivotto I.
        • Belardinelli L.
        • Poggesi C.
        • Cerbai E.
        • Mugelli A.
        Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
        Circulation. 2013; 127: 575-584
        • De Ferrari G.M.
        • Maier L.S.
        • Mont L.
        • Schwartz P.J.
        • Simonis G.
        • Leschke M.
        • Gronda E.
        • Boriani G.
        • Darius H.
        • Guillamon Toran L.
        • Savelieva I.
        • Dusi V.
        • Marchionni N.
        • Quintana Rendon M.
        • Schumacher K.
        • Tonini G.
        • Melani L.
        • Giannelli S.
        • Alberto Maggi C.
        • John Camm A.
        Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following an ELectricaL CardiOversion) study.
        Heart Rhythm. 2015; 12: 872-878